8th NovAliX Conference | Hybrid Event

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

Biophysics in Drug Discovery 2022 | European Edition

 Munich, Germany & Virtual    May 9-11, 2022

Keynote Speaker

In-cell NMR: a Powerful Approach for Drug Discovery (KL01)

Prof. Lucia BANCI
Prof. Lucia BANCI
UNIVERSITY OF FLORENCE, Sesto Fiorentino, Italy
Read more

Invited Speakers

Functionalizing Covalent Binders (IL07)

Dr Nir LONDON
Dr Nir LONDON
THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Read more

Positioning Biophysics on the Drug Discovery Map (IL05)

Dr Christine GENICK
Dr Christine GENICK
NOVARTIS PHARMA AG, Basel, Switzerland
Read more

Reactive Fragment Platforms for Covalent Hit ID (IL06)

Dr Emma GRANT
Dr Emma GRANT
GLAXOSMITHKLINE, Stevenage, United Kingdom
Read more

Exploration of Orthogonal E3 Ligases for Targeted Protein Degradation (IL10)

Dr Lena MÜNZKER
Dr Lena MÜNZKER
BOEHRINGER INGELHEIM, Vienna, Austria
Read more

Molecular Glues Stabilizing 14-3-3 Protein-Protein Interactions (IL09)

Dr Christian OTTMANN
Dr Christian OTTMANN
EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands
Read more

Manipulating RNA Function by Structural Dynamics (IL02)

Prof. Katja PETZOLD
Prof. Katja PETZOLD
KAROLINSKA INSTITUTET, Stockholm, Sweden
Read more

Structure-Based Design of a Phosphotyrosine-Masked, Cell Penetrant Small Molecule Covalently Targeting the E3 Ligase SOCS2 (IL08)

Dr Sarath  RAMACHANDRAN
Dr Sarath RAMACHANDRAN
UNIVERSITY OF DUNDEE, Scotland, United Kingdom
Read more

In-cell NMR to study RNA Structure and Folding (IL04)

Prof. Harald SCHWALBE
Prof. Harald SCHWALBE
J.W. GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany
Read more

Measuring Ligand Binding in Cells Using CETSA® (IL03)

Dr Joseph SHAW
Dr Joseph SHAW
ASTRAZENECA, Cambridge, United Kingdom
Read more

Fluorescent Nucleobase Analogues - minimally Perturbing Labels in Nucleic Acid Biophysics and Bioimaging as well as Drug Discovery (IL01)

Prof. Marcus WILHELMSSON
Prof. Marcus WILHELMSSON
CHALMERS UNIVERSITY OF TECHNOLOGY, Gothenburg, Sweden
Read more

Oral Communications

Binding of Small Molecules to Oligonucleotides in Drug Discovery (OC02)

Dr Nina GROSSMANN
Dr Nina GROSSMANN
MERCK HEALTHCARE, Darmstadt, Germany
Read more

The Use of Dual Targeted Bicycles® to Induce Localised CD137 Agonism (OC04)

Dr Peter BROWN
Dr Peter BROWN
BICYCLE THERAPEUTICS, Cambridge, United Kingdom
Read more

Biophysical Methods Enabling Structure-Based Drug Discovery on Membrane Protein Targets (OC05)

Dr Michael HENNIG
Dr Michael HENNIG
LEADXPRO AG, Villigen, Switzerland
Read more

The Biophysics in the Discovery of Potent cGAS Inhibitors (OC08)

Dr Manuel HILBERT
Dr Manuel HILBERT
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
Read more

Structure-based Design of RNA-Binding Small Molecules and their Binding Characterization via MST, (kin)ITC and SwitchSENSE Assays (OC01)

Dr Christian KERSTEN
Dr Christian KERSTEN
JOHANNES GUTENBERG UNIVERSITY, Mainz, Germany
Read more

Discovery and Characterization of Active Small Molecule Ligands Targeting the Function of Ubiquitin Specific Protease USP7 by a Catalytic Site Independent Mechanism (OC07)

Prof. Till MAURER
Prof. Till MAURER
IDEAYA BIOSCIENCES, South San Francisco, United States
Read more

Observing Reversible Engagement of KRAS Hotspot Mutants at the Switch-2 Pocket in Cells (OC03)

Mr Matthew ROBERS
Mr Matthew ROBERS
PROMEGA, Madison, United States

Applying Biophysical Interaction Methods to Characterize Binary and Ternary Complex Formation (OC06)

Dr Daniel SCHWARZ
Dr Daniel SCHWARZ
MERCK KGAA, Darmstadt, Germany
Read more

Towards Regulation of MDM2 via Stabilisation of a Complex Protein-Protein Interaction (OC09)

Mr Jake WARD
Mr Jake WARD
UNIVERSITY OF LEICESTER, Leicester, United Kingdom
Read more